Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
Globenewswire·2026-02-10 13:30
AGOURA HILLS, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- via IBN — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology, immunotherapy, and CNS-related diseases, today provided an update on key development progress achieved during 2025 and outlined its strategic direction as the Company enters 2026 with continued momentum across its pipeline. 2025: Continued Execution Across a Late-Stage, Diversified Pipeline Oncotelic trans ...